Document is current
Any future updates will be listed below
-
Authors
Berkyurek, Ahmet C https://orcid.org/0000-0002-7546-9191
Furlan, Giulia https://orcid.org/0000-0001-6134-6564
Lampersberger, Lisa https://orcid.org/0000-0002-3471-9908
Beltran, Toni https://orcid.org/0000-0002-5949-2615
Weick, Eva‐Maria https://orcid.org/0000-0002-3504-2572
Nischwitz, Emily
Cunha Navarro, Isabela https://orcid.org/0000-0002-6844-2361
Braukmann, Fabian https://orcid.org/0000-0003-2660-450X
Akay, Alper https://orcid.org/0000-0001-6825-4443
Price, Jonathan https://orcid.org/0000-0001-6554-5667
Butter, Falk https://orcid.org/0000-0002-7197-7279
Sarkies, Peter https://orcid.org/0000-0003-0279-6199
Miska, Eric A https://orcid.org/0000-0002-4450-576X
-
Funding
Funding for this research was provided by:
Cancer Research UK (C6946/A14492)
Cancer Research UK (C13474/A18583)
H2020 Marie Skłodowska-Curie Actions (747666)
Boehringer Ingelheim Fonds
Medical Research Council
Governo Brasil (205589/2014‐6)
Medical Research Foundation
Wellcome Trust (104640/Z/14/Z)
Wellcome Trust (092096/Z/10/Z)
- License Information
-
More Information
Article History
Received: 7 May 2020
Revised: 14 December 2020
Accepted: 19 December 2020
First Online: 3 February 2021
Conflict of interest
: The authors declare no competing interests. E.A.M. is a founder and director of STORM Therapeutics Ltd. STORM Therapeutics had no role in the design of the study and collection, analysis, and interpretation of data as well as in writing the manuscript.
